Nuvation Bio [NUVB] vs Regeneron [REGN] Detailed Stock Comparison

Nuvation Bio Inc.

NYSE
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Nuvation Bio Inc. wins in 3 metrics, Regeneron Pharmaceuticals, Inc. wins in 15 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Nuvation Bio Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 5.81 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 21.90 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -35.31 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -6.23 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 85.22% 31.41% Nuvation Bio Inc.
Operating Margin (TTM) -81.30% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -53.18% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -23.46% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-181.78M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 125.47% 25.39% Nuvation Bio Inc.
Price-to-Sales Ratio (TTM) 28.30 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $1.32B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 20.94 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 96.94% 84.95% Nuvation Bio Inc.
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-0.60 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.61 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 23.23% 2.55% Regeneron Pharmaceuticals, Inc.

Nuvation Bio Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

NUVB
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nuvation Bio Inc.-3.67%-0.42%7.03%8.26%-43.61%-44.99%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nuvation Bio Inc.125.47%179.53%-60.98%-51.96%-51.96%-51.96%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Nuvation Bio Inc. vs Regeneron Pharmaceuticals, Inc.

MetricNUVBREGN
Market Information
Market Cap i$1.75B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i2,882,977642,495
90 Day Avg. Volume i3,312,782617,765
Last Close$4.72$618.95
52 Week Range$1.57 - $9.75$476.49 - $821.11
% from 52W High-51.59%-24.62%
All-Time High$15.23 (May 24, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-69.01%-48.90%
Growth Metrics
Quarterly Revenue Growth6.33%0.03%
Quarterly Earnings Growth6.33%-0.08%
Financial Health
Profit Margin (TTM) i0.85%0.31%
Operating Margin (TTM) i-0.81%0.23%
Return on Equity (TTM) i-0.53%0.15%
Debt to Equity (MRQ) i21.909.51
Cash & Liquidity
Book Value per Share (MRQ)$0.88$304.65
Cash per Share (MRQ)$1.52$83.86
Operating Cash Flow (TTM) i$-173,427,008$4.98B
Levered Free Cash Flow (TTM) i$-115,776,248$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Nuvation Bio Inc. vs Regeneron Pharmaceuticals, Inc.

MetricNUVB (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-35.3114.21
PEG Ratio i-35.31-4.80
Price to Sales (TTM) i28.305.50
Price to Book (MRQ) i5.812.45
Market Capitalization
Market Capitalization i$1.75B$80.98B
Enterprise Value i$1.32B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i20.944.95
Enterprise to EBITDA i-6.2316.72
Risk & Other Metrics
Beta i1.610.40
Book Value per Share (MRQ) i$0.88$304.65

Financial Statements Comparison: Nuvation Bio Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNUVB (2025)REGN (2025)
Revenue/Sales i62.90M14.34B
Cost of Goods Sold i9.30M2.10B
COGS % of Revenue i14.8%14.6%
Gross Profit i53.60M12.24B
Gross Margin i85.2%85.4%
Research & Development i115.11M5.85B
Operating Income (EBIT) i-213.06M3.70B
Operating Margin i-338.7%25.8%
EBITDA i-188.37M5.00B
EBITDA Margin i-299.5%34.8%
Pre-Tax Income i-204.63M5.23B
Pre-Tax Income % of Revenue i-325.3%36.5%
Income Tax i0725.80M
Income Tax % of Revenue i0.0%5.1%
Net Income (Profit) i-204.63M4.50B
Profit Margin i-325.3%31.4%

Balance Sheet & Liquidity Metrics

MetricNUVB (2025)REGN (2025)
Cash & Equivalents i164.09M3.12B
Total Current Assets i571.52M18.02B
Total Current Assets % of Revenue i908.6%125.7%
Total Current Liabilities i82.23M4.37B
Total Current Liabilities % of Revenue i130.7%30.5%
Long-Term Debt i49.75M2.71B
Long-Term Debt % of Revenue i79.1%18.9%
Total Shareholders Equity i305.72M31.26B
Retained Earnings i-1.12B35.80B
Retained Earnings % of Revenue i-1,773.2%249.6%
Property, Plant & Equipment i3.92M1.54B

Cash Flow Statement Comparison

MetricNUVB (2025)REGN (2025)
Operating Cash Flow i-175.98M6.30B
Operating Cash Flow % of Revenue i-279.8%43.9%
Capital Expenditures i-354,0000
Free Cash Flow i-181.78M3.77B
FCF Margin i-289.0%26.3%
Debt Repayment i-11.90MN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricNUVBREGN
Shares Short i48.73M2.55M
Short Ratio i9.624.46
Short % of Float i23.23%2.55%
Shares Outstanding i346.50M105.72M
Float Shares i237.04M98.55M
% Held by Insiders i18.67%1.98%
% Held by Institutions i62.24%91.08%
% Held by Public i19.09%6.94%

Dividend Analysis & Yield Comparison: Nuvation Bio Inc. vs Regeneron Pharmaceuticals, Inc.

MetricNUVBREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026